Addressing blinding in classic psychedelic studies with innovative active placebos
International Journal of Neuropsychopharmacology · 2025
DOI: 10.1093/ijnp/pyaf023 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Neuropsychopharmacology, 2025. Verfasst von Jacob S Aday und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Anesthesiology, University of Michigan, Ann Arbor, MI, United States. Hauptthemen laut MEDLINE: Hallucinogens, Placebo Effect, Mental Disorders, Clinical Trials as Topic. Die Arbeit wurde bisher 30-mal zitiert (Crossref) und nennt 58 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Olle Engvist Foundation, NIAMS NIH HHS, VA R&D.
Abstract (Originalsprache)
Classic psychedelics have shown promise in the treatment of various neuropsychiatric disorders. However, weak blinding integrity has been argued to limit the interpretability of therapeutic effects observed in psychedelic clinical trials, highlighting the need to explore alternative active placebos. Here, we aimed to describe the drawbacks of current placebo conditions used in classic psychedelic studies, propose criteria for suitable active placebos, and review interventions that may putatively fit these criteria. Considerations for the characteristics of ideal active placebos in classic psychedelic studies include (1) acute psychoactive effects, (2) acute physiological effects, (3) onset and duration of acute effects, (4) safety, and (5) lack of therapeutic effects in the target disease. We identified several pharmacological agents that may have potential as active placebos in trials involving moderate-to-high doses of certain short-acting and long-acting classic psychedelics, as well as low-dose administration and microdosing regimes. To accurately assess the safety and efficacy of classic psychedelics as therapeutics, future research should apply a thoughtful process for selecting active placebos and consider ancillary strategies to improve blinding in trials involving these substances.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Anesthesiology, University of Michigan, Ann Arbor, MI, United States.
- Department of Neurobiology, Care Sciences and Society, Karolinska Institute, Sweden.
- Department of Neurology, Yale School of Medicine, New Haven, CT, United States.
- Neurology Service, VA Connecticut Healthcare System, West Haven, CT, United States.
- Department of Psychiatry, Yale School of Medicine, New Haven, CT, United States.
- Neuropsychiatry Firm, VA Connecticut Healthcare System, West Haven, CT, United States.
ORCID-Profile: Jacob S Aday, Otto Simonsson
Förderung
- Olle Engvist Foundation
- NIAMS NIH HHS
- VA R&D
- Vikram Sodhi Endowed Chair of Psychiatry
- Ceruvia Lifesciences
- Wallace Research Foundation
- Heffter Research Institute
- Clusterbusters, Inc
Zitieren
APA
Aday, J. S., Simonsson, O., Schindler, E. A. D., & D'Souza, D. C. (2025). Addressing blinding in classic psychedelic studies with innovative active placebos. International Journal of Neuropsychopharmacology. https://doi.org/10.1093/ijnp/pyaf023
Vancouver
Aday JS, Simonsson O, Schindler EAD, D'Souza DC. Addressing blinding in classic psychedelic studies with innovative active placebos. International Journal of Neuropsychopharmacology. 2025. doi:10.1093/ijnp/pyaf023
BibTeX
@article{Aday2025,
author = {Aday, Jacob S and Simonsson, Otto and Schindler, Emmanuelle A D and D'Souza, Deepak Cyril},
title = {Addressing blinding in classic psychedelic studies with innovative active placebos},
journal = {International Journal of Neuropsychopharmacology},
year = {2025},
doi = {10.1093/ijnp/pyaf023}
}
EUVIMED